PRKDC and acute myeloid leukemia: Similarly M3814, a selective DNA-PK inhibitor, potentiated the activity of ionizing radiation as well as the anthracycline topoisomerase II inhibitor, daunorubicin, alone or in combination with cytarabine, in AML cell lines and an AML PDX mouse model; this potentiation was only observed in p53 wild type AML cells (60).